18:23:20 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriBioteknik
EXACT Therapeutics är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av medicintekniska produkter. Produktportföljen är bred och inkluderar exempelvis tekniska plattformar för läkemedelstestning. Utöver huvudverksamheten erbjuds även tillhörande kringtjänster och mervärdesprodukter. Verksamheten drivs globalt med störst närvaro inom den nordiska marknaden. Bolaget gick tidigare under namnet Phoenix Solutions och har idag sitt huvudkontor i Oslo.

Kalender

2022-09-22 Kvartalsrapport 2022-Q2
2022-06-09 Ordinarie utdelning EXTX 0.00 NOK
2022-06-08 Årsstämma 2022
2022-04-27 Bokslutskommuniké 2021
2021-08-25 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-14 Ordinarie utdelning EXTX 0.00 NOK
2021-04-29 Bokslutskommuniké 2020
2020-07-27 Split EXTX 1:250
2020-07-24 Extra Bolagsstämma 2020
2021-12-22 14:22:02
EXACT Therapeutics AS Announces Allowance of Patent Application in Europe for
Acoustic Cluster Therapy (ACT®)

OSLO/LONDON, 22 December 2021: Christmas came early at EXACT Therapeutics AS
("EXACT-Tx", or "the Company" Euronext Growth: EXTX) as the clinical-stage
precision health company developing the proprietary ultrasound-mediated drug
delivery platform Acoustic Cluster Therapy (ACT®) for use across multiple
diseases, announces today that allowability has been found for its patent
application in Europe (publication no. EP3049117) for its innovative Acoustic
Cluster Therapy® technology.

The allowed patent claims cover EXACT-Tx`s unique microbubble/ microdroplet
formulation (PS101) and its use, co-administered with a range of pharmaceutical
agents for ultrasound mediated drug targeting. This is an important step in
securing EXACT-Tx's mission to enhance the therapeutic outcome of the standard
of care across drug classes for the benefit of patients across diseases.

Dr Masha Strømme, Executive Chair of the Board, commented: "We are delighted
with the decision of the European Patent Office in allowing this important
patent for ACT®, which complements the existing grant in China in November 2019
and in Japan in April 2021. This core patent family represents the foundation of
our dynamic IP strategy, which encompasses the use of ACT® with a variety of
therapeutics across a multitude of indications".
ENDS

For more information, please contact:

Dominic Moreland
EXACT Therapeutics
Email: dominic@exact-tx.com

Optimum Strategic Communications
Hollie Vile/ Manel Mateus/ Vici Rabbetts
Tel: +44 (0) 208 078 4357
Email: Exact@optimumcomms.com

About EXACT Therapeutics AS
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® follows a unique approach to ultrasound-mediated, targeted drug enhancement
- with the potential to significantly amplify the clinical utility of a wide
range of therapeutic agents across a multitude of indications including within
oncology (chemotherapy, immunotherapy), infectious diseases, and brain diseases.
www.exact-tx.com

About ACT®
oACT® is a proprietary formulation consisting of microbubbles and microdroplets
that are activated through the application of ultrasound with the consequent
increase in targeted delivery of a co-administered therapeutic agent.
oACT® is supported by a strong and broad preclinical package demonstrating
therapeutic enhancement in multiple oncology models (pancreatic, breast, colon,
prostate) as well as blood-brain barrier penetration.
oInitial focus of the Company is in oncology, however the ACT® platform has
potential across therapeutic areas (infectious diseases, CNS, immunotherapy) and
product classes.

Forward looking statements
This announcement and any materials distributed in connection with this
announcement may contain certain forward-looking statements. By their nature,
forward-looking statements involve risk and uncertainty because they reflect the
Company's current expectations and assumptions as to future events and
circumstances that may not prove accurate. A number of material factors could
cause actual results and developments to differ materially from those expressed
or implied by this forward-looking statement.